Eteplirsen Review Offers Lessons For FDA, Advocacy Groups, Industry

Agency reviewers believed the line between patient input and external intimidation had been crossed; early data from the Sarepta muscular dystrophy drug's flawed development program stoked patient community expectations and made regulatory review difficult.

FDA, patient advocates and rare disease drug developers should take away several lessons from the development and regulatory review of Sarepta Therapeutics Inc.'s Duchenne muscular dystrophy drug Exondys 51 (eteplirsen).

FDA learned the challenges of integrating the patient voice in the regulatory decision-making process without its reviewers and staff being...

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Product Reviews

More from Pink Sheet